Celebrating 30 years of Excellence and Innovation in GI cancer research

For 30 years, the AGITG and GI Cancer Institute have been working towards a world free from Gastro-Intestinal (GI) cancers.

Since 1991, we have conducted 60 clinical trials in Australia and internationally. These trials have given more than 7,000 GI cancer patients access to new treatments, 3-5 years earlier than they would have otherwise received them.

Our medical research has:
• Been integral to worldwide changes in medical practice in a number of GI cancers: oesophageal, colorectal and gastro-intestinal stromal tumour cancers,
• Provided patients with new cutting edge treatments and high care support not otherwise available,
• Led trials in the treatment of stomach, rectal and anal cancer, and
• Established surgical guidelines in Australia for pancreatic cancer.

Thank you to all of the patients, and their families, who have taken part in these trials to help improve treatments for future generations.

Thank you to our membership of expert medical professionals who continue to volunteer their time to advance GI cancer research.

We continue to raise awareness and funds for GI cancer, but we could not do this without our loyal community of supporters. We thank you for you dedication and continued generosity.

A look back at the last thirty years:

  • AGITG opens first clinical trials to patient participation under the auspices of the NHMRC Clinical Trials Centre, University of Sydney – two colorectal cancer studies from the USA
  • Total trials opened: 2
  • AGITG developed first trials for colorectal cancer and oesophageal cancer
  • Professor John Zalcberg OAM appointed Chair of the AGITG
  • Total trials opened since 1991: 4
  • First AGITG developed gastric cancer trial opens to patient participation
  • Total trials opened since 1991: 5
  • First AGITG Annual Scientific Meeting (ASM) held in Launceston, TAS
  • Total trials opened since 1991: 5
  • AGITG incorporated as Company Limited by Guarantee
  • First Board of Directors elected
  • Recruitment opens for patients for colorectal cancer clinical trials
  • Total trials opened since 1991: 7
  • AGITG and Trans Tasman Radiation Oncology Group (TROG) collaborate to develop a trial for rectal cancer patients
  • AGITG participates in trials developed by the European Organisation for Research and Treatment of Cancer (EORTC)
  • AGITG participates in trials for gastro-oesophageal cancer, advanced gastro-intestinal stromal tumours (GIST), advanced hepatocellular carcinoma and liver cancer
  • Total trials opened since 1991: 14
  • Russell Conley appointed as AGITG Executive Officer
  • AGITG accrues patients to a pancreatic cancer trial developed by the National Cancer Institute of Canada (NCIC)
  • AGITG collaborates with European Study Group for Pancreatic Cancer (ESPAC) for the first time for a pancreatic cancer trial
  • AGITG’s Gastro-Intestinal  Cancer Institute of Australia and New Zealand is launched and hosts public information forum
  • Total trials opened since 1991: 16
  • AGITG and the NCIC collaborate to develop a colorectal cancer clinical trial
  • Total trials opened since 1991: 17
  • First AGITG developed oesophago-gastric cancer trial
  • Advanced GIST study results published in the Lancet
  • Total trials opened since 1991: 18
  • His Honor Judge Alan Bishop is the first non-clinician to join the AGITG Board of Directors
  • First AGITG developed trial in colorectal cancer to accrue patients internationally
  • New Concepts Symposium is introduced at the AGITG Annual Scientific Meeting
  • First Research Fellow appointed
  • AGITG trials for oesophageal cancer, GIST, biliary tract, pancreatic, and colorectal cancer
  • Total trials opened since 1991: 23
  • First Cancer Australia infrastructure grant ‘Strengthening Cancer Carer’ awarded to AGITG
  • GI Cancer Institute held ‘Kick a Goal for Bowel Cancer’ in Martin Place, Sydney to raise awareness of the disease
  • Total trials opened since 1991: 23
  • AGITG meta-analysis for treatment of oesophageal cancer published in Lancet Oncology
  • CO.17 study results in New England Journal of Medicine
  • CO7 trial results published in journal of Clinical Oncology
  • AGITG collaborates with the University of Oxford to conduct a colorectal cancer clinical trial
  • Total trials opened since 1991: 24
  • AGITG consumer Advisory Panel established
  • AGITG and the NCIC collaborate to develop a second colorectal cancer clinical trial
  • Total trials opened since 1991: 25
  • The Alan Bishop Fund for GIST Research is established
  • Four AGITG developed clinical trials were launched to investigate new treatments for oesophageal cancer, gastric cancer and gastro-intestinal stromal tumour
  • AGITG participates in a rectal cancer clinical trial led by the EORTC
  • Total trials opened since 1991: 30
  • Four AGITG developed clinical trials were launched to investigate new treatments for oesophago-gastric cancer, gastrointestinal stromal tumour, colorectal cancer and rectal cancer
  • AGITG participates in a pancreatic cancer trial led by Groupe Cooperateur Multidiciplinaire en Oncologie (GERCOR)
  • AGITG participates in a colorectal cancer trial led by Cancer Clinical Trials Unit, Scotland (CaCTUS)
  • MAX study results published in Journal of Clinical Oncology
  • The Gutsy Challenge for children is launched
  • Total trials opened since 1991: 36
  • AGITG developed and led a trial for colorectoral cancer
  • Upper and Lower GI Working Parties established to identify gaps in research and develop new research concepts
  • Total trials opened since 1991: 37
  • Five AGITG developed Clinical trials open to patient participation investigating new treatments for biliary tract cancer, pancreatic cancer, colorectal cancer and cancer of the oesophago-gastric junction
  • External Review of AGITG conducted by three world leaders in GI cancer research
  • The GI Cancer Institute Engage Program launched
  • Total trials opened since 1991: 42
  • AGITG and NCIC collaborate on the next colorectoral cancer trial
  • AGITG and the Australasian Pancreatic Club hold the inaugural Pancreas Cancer Research Workshop
  • The Gutsy Challenge further developed to include adults
  • Engage Community Forums develop
  • Three AGITG trials conducted in Europe, Korea and Canada for the First time
  • Best New Concept Award and Kristian Anderson Award Launched
  • First Preceptorship in Colorectal cancer held
  • Total trials opened since 1991: 43
  • Professor Tim Price appointed as Chair of the AGITG
  • AGITG collaborates with the Scandinavian Sarcoma Group to develop a trial for gastrointestinal stromal tumour
  • Aspirin based clinical trial for colorectal cancer led by an international collaboration from Australia, Singapore and UK opens to patient participation
  • Total trials opened since 1991: 45
  • Adjuvant GIST study results published in Journal of Clinical Oncology
  • AGITG membership grows to over 1,000
  • Results from INTEGRATE and GAP clinical trials are presented at American Society of Clinical Oncology Conference (ASCO) in Chicago
  • Pancreatic Cancer Surgical Guidelines Workshop held to develop national guidelines
  • Inaugural meeting of the Commonwealth Neuroendocrine Tumor Group (CommNETS)
  • AGITG developed trial for neuroendocrine tumours
  • First Gutsy Challenge trek held with members and community climbing Mt Kilimanjaro
  • First two Innovation Fund Grants supported by community based fundraising for DOCTOR Oesophageal cancer study and a Gastric cancer study
  • Total trials opened since 1991: 46
  • Three trials open for patient enrolment: INTEGRATE II in Stomach/Oesophageal cancer, NABNEC in Pancreatic cancer, and ACTICCA-1 in Gallbladder and Biliary Tract cancer
  • 18 publications and 12 presentations
  • MONARCC Colorectal cancer trial awarded Innovation Fund Grant supported by community based fundraising
  • Gutsy Challenge: Cambodia trek led by Prof Chris Karapetis
  • Total trials opened since 1991: 49
  • Russell Conley becomes AGITG Chief Executive Officer
  • The DYNAMIC-III trial in colorectal cancer opens
  • First preceptorship in Rectal cancer
  • 7 publications and 14 presentations
  • RENO (Rectal) wins Innovation Fund Grant supported by community based fundraising
  • Gutsy Challenge: Mt Aconcagua climb led by Professor Niall Tebbutt and the Larapinta Trail led by Dr Lorraine Chantrill
  • Total trials opened since 1991: 50
  • Five new trials open: MODULATE, MONARCC and LIBERATE in Colorectal cancer, and DYNAMIC-Rectal and SPAR in Rectal cancer
  • CONTROL NETs (Neuroendocrine tumours) completes patient enrolment
  • 9 publications and 9 presentations including DOCTOR presentation at ESMO
  • OXTOX Colorectal cancer trial wins Innovation Fund Grant supported by community based fundraising
  • Gutsy Challenge: Two Overland Track treks led by Prof Steve Ackland, and Consumer Advisory Panel members Jan Mumford and Gill Worden
  • Total trials opened since 1991: 55
  • Three new trials open: MASTERPLAN and DYNAMIC-Pancreas in Pancreatic cancer, and RENO in Rectal cancer
  • 5 publications and 5 presentations
  • Inaugural Idea Generation Workshop to generate new GI cancer research
  • Launched the Endorsed Study Model and Translational Research Model
  • The first Japanese site in an AGITG trial opens for Stomach/Oesophageal trial INTEGRATE II
  • FORECAST-1 Colorectal cancer trial awarded Innovation Fund Grant supported by community based fundraising
  • Gutsy Challenge: Southern Alps climb in NZ led by Prof Tim Price, and Cape to Cape trek in WA led by Dr Lorraine Chantrill
  • Total trials opened since 1991: 58
  • Dr Lorraine Chantrill appointed as Chair of the AGITG, GI Cancer Institute and Scientific Advisory Committee
  • Dal Wills retired after more than 16 years leading AGITG Administration
  • AGITG membership grows to over 1,400
  • 7000+ patients recruited into AGITG trials since 1991
  • Two new colorectal trials, FORECAST-1 and OXTOX, open to patient enrolment
  • The first US site in an AGITG trial opens for INTEGRATE II
  • 7 publications and 6 presentations including CONTROL NETs presentations at ASCO and ESMO
  • MODULATE colorectal trial completes patient enrolment
  • Second annual Idea Generation Workshop held to generate new research in Oesophageal cancer
  • First preceptorship held in Gastric cancer
  • Christine Aiken Memorial Award for Excellence in AGITG Study Coordination announced
  • First substudy – RANDOMS for pancreatic cancer – supported by a bequest
  • Three Innovation Fund grants awarded thanks to community based fundraising: CONTROL NETS translational substudy in Neuroendocrine tumours, MASTERPLAN translational substudy in Pancreatic cancer, and a Colorectal cancer study
  • Total trials opened since 1991: 60
Share